Evidence map›Paper›PMID 39235661›Full record

ArticleProbiotics and antimicrobial proteins2025

Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review.

Ailim Margarita Carías Domínguez, Dimas de Jesús Rosa Salazar, Juan Pablo Stefanolo, Maria Claudia Cruz Serrano, Isabel Cristina Casas, Julio Ricardo Zuluaga Peña

Abstract readScoping Review
In one paragraph

Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Gut microbiota in health and disease.Molecular biomedicine · 2026
    Review
  3. The Gut-Heart Axis: A Microbiome-Centered Perspective on Heart Failure.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Correlation Between Dysbiosis and Atrial Fibrillation: What's New?International journal of molecular sciences · 2025
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ailim Margarita Carías DomínguezFundación Santa Fe de Bogotá (Santa Fe de Bogotá Foundation), Bogotá, Colombia. ailimcarias@gmail.com.ORCID 0000-0002-6655-9216
Dimas de Jesús Rosa SalazarGrupo de Investigación del Caribe y Centroamérica Para La Microbiota, Probióticos y Prebióticos (Research Group of the Caribbean and Central America for Microbiota, Probiotics and Prebiotics) (GICCAMPP), Bogotá, Colombia.ORCID 0009-0009-4073-6120
Juan Pablo StefanoloHospital de Gastroenterología Carlos Bonorino Udaondo (Carlos Bonorino Udaondo Gastroenterology Hospital), CABA-Buenos Aires, Argentina.ORCID 0000-0003-0679-3470
Maria Claudia Cruz SerranoSOCOPAC, Sanofi, Bogotá, Colombia.ORCID 0009-0003-7413-516X
Isabel Cristina CasasOdds Epidemiology SAS, Bogotá, Colombia.ORCID 0000-0002-3769-5016
Julio Ricardo Zuluaga PeñaOdds Epidemiology SAS, Bogotá, Colombia.ORCID 0000-0002-2617-1233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysbiosis is a clinical condition marked by altered gut microbiota resulting from external and internal host factors. It is strongly associated with gastrointestinal and extraintestinal alterations, so its symptomatology is broad and nonspecific. To date, gaps remain that limit professionals from making a timely diagnosis and prescribing the appropriate treatment. We aim to synthesize existing literature regarding clinical parameters for the early detection of patients with intestinal dysbiosis and the clinical events in which the use of probiotics as adjuvant therapy is most frequently reported. A scoping review of the literature was conducted in PubMed, Embase, Cochrane, and BVS (Biblioteca Virtual en Salud in Spanish) databases for articles published in the last 5 years. Primary studies and literature reviews related to clinical presentation, dysbiosis screening, and probiotics as adjuvant therapy for adult and pediatric patients were included. Twenty-three articles were retrieved in which the most frequently reported symptoms were abdominal distension, abdominal pain, and diarrhea. Chronic and metabolic diseases where the conditions most strongly associated with dysbiosis. Depending on symptomatology and etiology, dysbiosis is often treated with probiotics. Dysbiosis, often linked to diarrhea, should be considered with other symptoms like abdominal distension and pain, along with predisposing conditions and patient risk factors. Probiotics are commonly used as co-adjuvant treatments for antibiotic-associated diarrhea, irritable bowel syndrome, and childhood allergic diseases. The most commonly used probiotics were Weizmannia coagulans (formerly B. coagulans), Alkalihalobacillus clausii (formerly Bacillus clausii), Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Saccharomyces boulardii.

Indexed as

DysbiosisGastrointestinal MicrobiomeProbioticsHumansDysbiosisGut microbiotaProbioticsSymptomsTherapeutic uses

Identifiers

PMID39235661
PMCPMC11832579

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.